KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Payables (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Payables readings, the most recent being $65.1 million for Q4 2025.

  • On a quarterly basis, Payables fell 38.75% to $65.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.1 million, a 38.75% decrease, with the full-year FY2025 number at $65.1 million, down 38.75% from a year prior.
  • Payables hit $65.1 million in Q4 2025 for Esperion Therapeutics, down from $132.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $132.4 million in Q3 2025 to a low of $12.8 million in Q2 2022.
  • Median Payables over the past 5 years was $28.9 million (2021), compared with a mean of $47.5 million.
  • Biggest five-year swings in Payables: tumbled 66.22% in 2021 and later skyrocketed 345.48% in 2025.
  • Esperion Therapeutics' Payables stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 234.9% to $106.2 million in 2024, then crashed by 38.75% to $65.1 million in 2025.
  • The last three reported values for Payables were $65.1 million (Q4 2025), $132.4 million (Q3 2025), and $129.5 million (Q2 2025) per Business Quant data.